Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Nature Reviews. Cancer|August 6, 2020
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacyDaniela Bruni, Helen K Angell, Jérôme Galon
Oncoimmunology|May 7, 2014
The immune landscape of human tumors: Implications for cancer immunotherapyGabriela Bindea, Bernhard Mlecnik, Helen K Angell, et al.
Immunity|July 30, 2013
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signaturesJérôme Galon, Helen K Angell, Davide Bedognetti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2019
The Immunoscore: Colon Cancer and BeyondHelen K Angell, Daniela Bruni, J Carl Barrett, et al.
Cancer Research Communications|October 11, 2023
Immune Cell Abundance and T-cell Receptor Landscapes Suggest New Patient Stratification Strategies in Head and Neck Squamous Cell CarcinomaMaria Secrier, Lara McGrath, Felicia Ng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 29, 2017
Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I TrialKenneth S Thress, Vivien Jacobs, Helen K Angell, et al.
British Journal of Cancer|October 5, 2020
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancerBenjamin C Creelan, Tammie C Yeh, Sang-We Kim, et al.
Science Translational Medicine|February 26, 2016
The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasisBernhard Mlecnik, Gabriela Bindea, Amos Kirilovsky, et al.
Science Translational Medicine|March 21, 2014
Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patientsBernhard Mlecnik, Gabriela Bindea, Helen K Angell, et al.
Lung Cancer (Amsterdam, Netherlands)|May 5, 2023
Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket studyMatthew G Krebs, Jean-Pierre Delord, Thomas R Jeffry Evans, et al.
Pageof 3